VIR BIOTECHNOLOGY

60 articles about VIR BIOTECHNOLOGY

• Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

  9/20/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV).

• Vir Biotechnology to Participate in Upcoming September 2023 Investor Healthcare Conferences

  8/29/2023

  Vir Biotechnology, Inc. announced that management will be participating in the following upcoming investor conferences during the month of September.

• Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

  8/3/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

• Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023

  7/26/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023.

• Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

  7/20/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.

• Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

  6/29/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023.

• Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

  6/25/2023

  Brii Biosciences Limited announced that its strategic partners, Vir Biotechnology, Inc. and VBI Vaccines, Inc., presented results from multiple clinical studies for the treatment and prevention of chronic hepatitis B viral infection at the European Association for the Study of the Liver Congress 2023 that further support the clinical evaluation of Brii Bio's assets as a potential best-in-class functional cure for chronic HBV infection.

• Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

  6/24/2023

  Vir Biotechnology, Inc. announced new data from its robust hepatitis B and D virus portfolio that were presented at the EASL™ Congress.

• Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023

  6/7/2023

  Vir Biotechnology, Inc. announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus and hepatitis D virus have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2023, taking place in Vienna from June 21-24.

• Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

  6/5/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.

• Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

  5/17/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT.

• Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

  5/15/2023

  Vir Biotechnology, Inc. announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer.

• Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

  5/11/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) in hepatitis B virus (HBV) immune-active, treatment-naïve adults.

• Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/4/2023

  Vir Biotechnology, Inc. provided a corporate update and reported financial results for the first quarter ended March 31, 2023.

• Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference

  5/3/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ET.

• Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention

  5/2/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it received a new $10 million grant from the Bill & Melinda Gates Foundation to support Vir’s novel T cell vaccine development program.

• Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference

  4/11/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, at 12:00 p.m. PT / 3:00 p.m. ET.

• Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

  3/8/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET.

• Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

  2/28/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET.

• Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  2/23/2023

  Vir Biotechnology, Inc. today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.